tab albendazole price Formulation Analysis-NEWS-Dingzhou Kangquan Pharmaceutical - Professional Veterinary Medicine Manufacturer

Introduction

Albendazole tablets represent a critical anthelmintic medication widely utilized in both human and veterinary medicine for the treatment of parasitic worm infections. This technical guide provides an in-depth analysis of the formulation, manufacturing process, performance characteristics, failure modes, and relevant industry standards pertaining to albendazole tablets. Albendazole’s mechanism of action involves inhibiting microtubule polymerization in parasitic worms, leading to their immobilization and eventual elimination. The consistent delivery of a bioavailable dosage form is paramount for therapeutic efficacy, making manufacturing quality control and material integrity key industry concerns. This document caters to pharmaceutical manufacturers, quality assurance professionals, regulatory affairs personnel, and procurement managers requiring a comprehensive understanding of this essential medication. Understanding variations in raw material sourcing, polymorphism, and excipient compatibility directly impacts the final product’s stability and bioavailability, creating significant challenges for consistent production.

Material Science & Manufacturing

Albendazole (methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate) is a benzimidazole derivative exhibiting limited aqueous solubility, posing formulation challenges. Raw materials typically include albendazole API (Active Pharmaceutical Ingredient) sourced from various chemical synthesis routes, lactose monohydrate (a common diluent), sodium starch glycolate (a disintegrant), magnesium stearate (a lubricant), and potentially colloidal silicon dioxide (a flow aid). The crystalline form of albendazole significantly influences its dissolution rate; polymorphic transformations can occur during processing, affecting bioavailability. Manufacturing involves dry granulation or direct compression techniques. Dry granulation, employing roller compaction, is preferred for improving flowability and compressibility. Critical process parameters include roller gap settings, compaction force, granule size distribution, and blending uniformity. Direct compression necessitates excellent powder flow properties achieved through optimized particle size distribution and excipient selection. Tablet compression utilizes rotary tablet presses with strict control over compression force, dwell time, and tablet weight. Coating, typically with a film coating containing polymers like hypromellose (HPMC), is applied to improve swallowability, protect the API from degradation, and control drug release. Quality control at each stage—API characterization (HPLC purity, particle size analysis, polymorphic form identification via X-ray diffraction), blend uniformity testing, in-process weight variation, hardness, and disintegration testing, and finished product dissolution testing—is crucial. Chemical compatibility studies between albendazole and excipients are essential to prevent degradation and ensure long-term stability.

Performance & Engineering

The primary performance criterion for albendazole tablets is bioavailability, which is directly linked to dissolution rate and absorption in the gastrointestinal tract. Bioavailability is affected by the drug’s low aqueous solubility and the pH-dependent nature of its dissolution. Engineering considerations include optimizing tablet formulation to enhance dissolution, potentially through solid dispersion techniques (dispersing albendazole in a hydrophilic polymer matrix). The mechanical strength of the tablet (hardness, friability) must withstand handling, packaging, and transportation without compromising dosage accuracy. Force analysis during compression reveals the relationship between compression force, tablet density, and porosity. Environmental resistance assessment involves evaluating stability under varying temperature and humidity conditions as per ICH guidelines. Compliance requirements include adherence to Good Manufacturing Practices (GMP) regulations outlined by regulatory bodies such as the FDA (US Food and Drug Administration) and EMA (European Medicines Agency). Dosage form uniformity is ensured through meticulous weight variation control during compression, minimizing deviations from the target weight. Drug release profiles are determined in vitro using dissolution apparatuses, ensuring the tablet releases albendazole at a predetermined rate. Packaging materials (blister packs or bottles) must provide adequate protection against moisture, light, and oxygen to maintain stability.

Technical Specifications

Parameter	Specification	Test Method	Acceptance Criteria
Albendazole API Assay	≥ 99.0%	HPLC	Complies
Related Substances	≤ 0.5% (individual impurity)	HPLC	Complies
Identification	Positive	IR Spectroscopy	Complies
Dissolution (USP Type II) – 30 minutes	≥ 75%	HPLC	Complies
Water Content (API)	≤ 0.5%	Karl Fischer Titration	Complies
Tablet Hardness	40-80 N	Tablet Hardness Tester	Complies

Failure Mode & Maintenance

Common failure modes for albendazole tablets include tablet friability and chipping due to insufficient hardness, capping or lamination resulting from air entrapment during compression, sticking to punches due to inadequate lubricant levels, and dissolution failures caused by polymorphic transformations or excipient incompatibility. Degradation of albendazole API can occur due to oxidation or hydrolysis, leading to a reduction in potency. Microbial contamination is a potential failure mode, requiring stringent adherence to GMP during manufacturing. Failure analysis involves root cause investigation utilizing techniques such as scanning electron microscopy (SEM) to examine tablet microstructure, differential scanning calorimetry (DSC) to assess polymorphic forms, and HPLC to quantify API degradation products. Preventative maintenance of tablet presses (regular lubrication, die cleaning, punch replacement) is crucial. Proper storage conditions (cool, dry place protected from light) are essential to maintain stability. Routine stability testing (accelerated and long-term) is vital to identify potential degradation pathways and establish appropriate expiry dates. Corrective and Preventative Action (CAPA) systems should be implemented to address identified failures and prevent recurrence. Proper training of personnel on GMP principles and standard operating procedures (SOPs) minimizes human error.

Industry FAQ

Q: What are the critical quality attributes (CQAs) for albendazole tablets and how are they monitored?

A: CQAs include API assay, dissolution rate, tablet hardness, and impurity levels. They are monitored through rigorous testing at various stages of manufacturing – raw material testing (API purity), in-process control (blend uniformity, tablet weight variation), and finished product testing (dissolution, assay, impurity profile). Statistical process control (SPC) is often employed to track CQAs and identify trends that may indicate deviations from specifications.

Q: How does polymorphism affect the bioavailability of albendazole?

A: Albendazole exhibits polymorphism, and different crystalline forms possess varying dissolution rates. A less soluble form can lead to reduced bioavailability. Therefore, controlling the polymorphic form during manufacturing and ensuring it remains stable during storage is critical. X-ray diffraction is used to confirm the desired polymorph.

Q: What are the challenges associated with formulating albendazole due to its low solubility?

A: The primary challenge is achieving adequate dissolution to ensure sufficient drug absorption. Strategies to overcome this include micronization of the API, solid dispersion techniques (using hydrophilic polymers), and the addition of surfactants to enhance wetting and solubility.

Q: What are the common excipients used in albendazole tablet formulations and what roles do they play?

A: Common excipients include lactose monohydrate (diluent), sodium starch glycolate (disintegrant), magnesium stearate (lubricant), and colloidal silicon dioxide (flow aid). Lactose provides bulk, sodium starch glycolate facilitates tablet breakup, magnesium stearate reduces friction during compression, and colloidal silicon dioxide improves powder flow.

Q: How are stability studies conducted to determine the shelf life of albendazole tablets?

A: Stability studies are conducted according to ICH guidelines, involving storage of tablets under controlled temperature and humidity conditions (accelerated and long-term). Samples are periodically analyzed for API assay, degradation products, dissolution, and physical characteristics. Data is used to determine the shelf life and recommended storage conditions.

Conclusion

Albendazole tablet manufacturing necessitates a comprehensive understanding of material science, pharmaceutical engineering principles, and stringent quality control measures. The low aqueous solubility of albendazole presents a significant formulation challenge, requiring careful selection of excipients and optimization of manufacturing processes to ensure consistent bioavailability. Thorough characterization of the API, control of polymorphic forms, and adherence to GMP regulations are crucial for producing a safe and efficacious medication.

Future advancements in albendazole formulations may focus on novel drug delivery systems, such as nanoparticles or lipid-based formulations, to further enhance solubility and bioavailability. Continuous monitoring of manufacturing processes, coupled with robust failure analysis and preventative maintenance, will be essential for maintaining product quality and minimizing the risk of recalls. Collaboration between pharmaceutical manufacturers, regulatory agencies, and researchers will contribute to the ongoing improvement of albendazole tablet technology and accessibility.

Apr . 01, 2024 17:55 Back to list

tab albendazole price Formulation Analysis